Drug Type Radiopharmaceuticals and diagnostic agent, Peptide Conjugate Radionuclide |
Synonyms gallium (68Ga) oxodotreotide |
Target |
Action antagonists |
Mechanism SSTR2 antagonists(Somatostatin receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date Canada (24 Feb 2022), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Neuroendocrine Tumors | Canada | 24 Feb 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diagnostic agents | IND Approval | China | 14 Mar 2025 |